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Abstract A group of 31 oncohae- 
mopathic patients (17 male, mean 
age 44 + 6 years), diagnosed as hav- 
ing primary deep fungal infection 
involving the lungs, were retrospec- 
tively evaluated. When infection 
was suspected on a clinical basis 
the major associated risks for 
death were the duration of bone 
marrow aplasia (12 + 7 versus 
21 +6 days, P<0.001), increase in 
white blood cells and, in particular, 
prolonged granulocytopenia (11 + 5 
versus 24 + 8 days, P< 0.001) when 
survivors were compared with pa- 
tients, who died. Our therapeutic 
empirical approach was based on 
the association of i.v. amphotericin 
B, 1 mg kg-  1 day-  1, with oral 5- 
fluorocytosine (5-FC) 150 mg kg-1 
day-1. Only 9 subjects received 
combination therapy for more than 
7 days. For majority of them, oral 
5-FC was interrupted because of 
altered compliance or sustained liv- 
er damage. A X 2 test for indepen- 
dent parameters showed 
(P = 0.0021) a concentration of 
deaths among patients who re- 
ceived amphotericin B alone (15/ 
22); none of the patients treated 
with amphotericin B + 5-FC (9 
cases) died. Results generally sug- 
gest that a more favourable out- 
come was statistically associated 
with empirical antifungal combina- 
tion therapy in deep fungal infec- 
tion, although both treatment re- 
gimens showed effectiveness in 
terms of survival. Nevertheless the 
low 5-FC compliance and the small 
sample do not indicate the safe use 
of this drug in a large population. 
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Introduction 
Fungal infections are commonly associated with death 
among leukaemic patients undergoing chemotherapy 
[3, 5]. Pulmonary infection due to invasive aspergillosis 
appears as one of the most frequent causes of morbidi- 
ty in neutropenic (polymorphonuclear neutrophils 
< 500/pA) leukaemic patients [2, 11, 13] often associated 
with a high mortality rate [19]. Difficulties deriving 
from in vivo diagnostic procedures partly explain the 
poor outcome of these infections [1, 16]. 
Risk factors for developing deep fungal infection 
(DFI) have been extensively studied, and granulocyto- 
penia [9], steroids or a prolonged broad-spectrum anti- 
biotic regimen [16, 19] and haematological remission 
[17] appear to be the most frequently associated 
causes. 
Empirical pharmacological ntifungal treatment is 
still the most common approach when DFI is suspected 
on a clinical basis. In this report we retrospectively 
evaluated the role of antifungal therapy in relationship 
to the outcome of DFI in a group of oncohaemopathic 
patients. 
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Patients and methods 
A group of 31 consecutive oncohaemopathic patients (17 male), 
diagnosed for suspected DFI with primary pulmonary involve- 
ment and treated with early empirical antifungal therapy, were 
evaluated. In Table 1 patient characteristics are summarized. All 
the subjects presented suspected DFI during aplasia due to the 
haematological illness or the drugs employed. Patients were ex- 
periencing a febrile episode (temperature >38 ~ and a treat- 
ment of broad-spectrum antibiotics (amikacin plus ceftazidime 
plus vancomycin) was instituted according to the most recent ad- 
vice [6]. In all cases lung involvement was proven after X-ray ex- 
amination. 
Twice a day blood cultures were obtained and twice a week 
samples from stools, urine, nasal and bronchial secretions (aspi- 
rates and/or broncho-alveolar vage, BAL) were taken to obtain 
diagnostic onfirmation. Microbiological research was conducted 
on BAL samples to exclude infections from other pathogens 
(Pneumocystis carinii, Legionella, viruses and rare bacterial spe- 
cies). 
Fever refractory to antibacterial therapy for more than 5 days 
was then treated with empirical antifungal therapy based upon 
the association between i.v. amphotericin B (AmpB) at a mean 
dose of i mg kg -1 day -1 and oral 5-fluorocytosine (5-FC) at a 
dose of 150 mg kg -1 day-1. A close monitoring of the side-effects 
of these drugs was performed. Early liver damage due to the use 
of-5-FC determined drug suspension within 7 days in 22 patients; 
two therapy groups were therefore selected. The mean time of 
antifungal treatment was 27 + 4 days and this did not significantly 
differ between the therapy groups. An oral nistatin regimen 
(three times daily) was instituted as an anti-Candida prophylactic 
therapy. Onset of DFI, defined according the criteria of Gerson 
[8, 10], age, duration of granulocytopenia, aplasia, leukaemic sta- 
tus, white blood cell (WBC) count and the kind, dose and dura- 
tion 0f antifungal therapies were correlated to the vital progno- 
sis. : : 
Student's t-test was applied for the variables considered in the 
two groups, according to the outcome of the infective episode. 
Moreover a X 2 test was performed in the therapy groups, always 
related to vital prognosis. A P value less than 0.05 was considered 
statistically significant. 
Results 
The morta l i ty  rate for DF I  compl icat ing haemato log i -  
cal mal ignancies was approx imate ly  50% in our sample  
(16 out of 31 pat ients) .  
Cul ture f rom BAL  was possib le in 9 out of 31 cases. 
Microbio logica l  conf i rmat ion of DF I  was obta ined  in 
24 cases (84%); in 2 out  of 9 pat ients  a posit ive BAL  
culture was obtained.  Aspergillus species were present  
in 90% of posit ive cases (22 out of 24 cor responding to 
2/3 of the total  sample)  and Cryptococcus was identif-  
ied in 5 out  of 24 pat ients  (20%).  Cryptococcus was iso- 
lated f rom BAL  and serological  conf i rmat ion was ob- 
ta ined at the same time. For  7 pat ients  (16%) there was 
no microbio log ica l  conf i rmat ion for their  suspected 
DF I ;  2 of them completed  an ant i fungal  reg imen with 
both AmpB and 5-FC. The mean t ime of onset  of DF I  
did not differ signif icantly between survivors and non- 
survivors (15 + 5 and 17+ 3 days respect ively)  but  the 
Table 1 Patients' characteristics. (AML Acute myelocytic leu- 
kaemia, ALL acute lymphocytic leukaemia, CML-BC blastic cri- 
sis of chronic myelogenous leukaemia) 
Age (years) 44 + 6 
Range 16-52 
Gender (M/F) 17/14 
Malignancy 
AML 15 
ALL 11 
CML-BC 2 
Lymphoma 3 
Complete remission 20 
Residual eukaemia 11 
Microbiological confirmation 24 
Table 2 Risk factor analysis associated with the outcome of deep 
fungal infection (DF1). (AmpB Amphotericin B, 5-FC 5-fluorocy- 
tosine, WBC white blood cells) 
Potential risk factor Survivors Non-survivors P 
(n=16) (n=15) 
Age (years) 43 + 5 45 + 2 NS 
AML 7/16 8/15 NS 
ALL 6/16 5/15 NS 
BC 1/16 1/15 NS 
Lymphoma 2/16 1/15 NS 
Aplasia (days) 12 + 7 21 + 6 < 0.001 
Onset of DFI (days) 15+5 17+3 NS 
Granulocytopenia (days) 11+5 24+- 8 < 0.001 
Treatment AmpB 7/22 15/22 < 0.01 
Treatment AmpB + 5-FC 9/9 0/9 < 0.0001 
Remission 12/16 8/15 NS 
Increased WBC count 12/16 2/15 <0.0001 
durat ion of bone marrow aplasia and granu locytopen ia  
were strictly re lated to the prognosis  (P<0.001 be- 
tween the two groups) as well  the increase in white 
b lood cells (P  < 0.0001). 
We observed a signif icant di f ference (P<0.05)  be- 
tween groups when the white b lood cell increase was 
compared  according to the di f ferent t reatments  ad- 
opted;  the number  of pat ients who presented  a cell in- 
crease was higher in the AmpB +5-FC group. More -  
over  the white cell count at the onset of a febri le epi- 
sode and evidence of pu lmonary  inf i l t rat ion were simi- 
lar in both groups. 
Haemato log ica l  remiss ion was present  in 12 out of 
16 survivors and in 8 out  of 15 of those who died, but  
the di f ference was not significant. No di f ferences in age 
or k ind of mal ignancy were found, as i l lustrated in Ta- 
ble 2. 
If we look at the t reatment  groups (AmpB + 5-FC or 
AmpB) ,  15 out of 22 pat ients  died in the AmpB group 
while 0 out of 9 died in the AmpB + 5-FC group. There  
were 7 and 9 survivors respect ively in the two therapy 
groups. A~ 2 analysis fo r  independent  parameters ,  ap- 
pl ied to these groups  according to the outcome,  re- 
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vealed a significant concentration of deaths in the 
AmpB group (P=0.0021). No differences were ob- 
served among the survivors in terms of the duration of 
different treatments (26 + 9 days for AmpB and 24+ 5 
days for AmpB + 5-FC). 
Discussion 
The present results principally emphasize the better 
outcome for DFI  retrospectively encountered in the 
group of oncohaemopathic patients treated with anti- 
fungal combination therapy (AmpB + 5-FC). 
The use of systemic AmpB is still relevant for the 
treatment of DFI  in leukaemic patients especially when 
an empirical approach cannot be delayed [12]. A pro- 
phylactic use of AmpB is also proposed in patients who 
have been previously diagnosed as having DFI  [18]. 
Pharmacological studies [4, 15] suggest he rationale for 
the use of an associated antifungal therapy that can 
provide a wide spectrum and possibly a synergistic ef- 
fect, as requested in our sample. 
Although combination therapy was considered to of- 
fer no advantages in terms of survival [20], our results 
seem to encourage the use of associated 5-FC. Nev- 
ertheless 5-FC compliance and hepatic failure (the 
causes for suspension of 5-FC) could be related to a 
more severe fungal infection and a poorer prognosis. In 
fact, AmpB also significantly improved the vital prog- 
nosis for the infection (see Table 2). 
Other results on the risk factors associated with a 
poor outcome for this infection generally reflect, in our 
study, the recent suggestions of Ribrag [17] except for 
the remission of the underlying disease, which was 
higher in terms of the number of survivors but not sig- 
nificantly linked with a better outcome. Microbiological 
confirmation for aspergillosis was higher than that 
quoted in the literature [7] but we cannot exclude the 
possibility of contamination from nasal secretion (posi- 
tive for Aspergillus species in 29/31 cases and in 22/22 
patients with positive bronchial secretion culture) as an 
adjunctive risk for pulmonary aspergillosis during a 
neutropenic phase [14]. No nasal antifungal prophylaxis 
was adopted. A presumptive diagnosis of pulmonary 
aspergillosis (or at least fungal infection) in the non- 
microbiologically confirmed patients was made accord- 
ing to the criteria of Gerson [8, 10] and after infection 
from other pathogens had been excluded (see Patients 
and methods). 
In conclusion we retrospectively found that the use 
of a combination antifungal therapy could be effective 
in suspected DFI  complicating haematological malig- 
nancies. The low 5-FC compliance does not warrant he 
empirical use of this drug in a large population. 
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